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ABSTRACT 
Antimicrobial  peptides  are  the  upcoming  therapeutic  molecules  as  alternative 
drugs to the existing antibiotics owing to their potent action against pathogenic 
microorganisms. In this study, to obtain an antimicrobial peptide with a broad 
range of activity, the synthetic cationic antimicrobial peptide was designed by 
using in silico tools viz., antimicrobial peptide database, protparam, hierarchical 
neural  network.  Later,  the  peptide  was  translated  back  into  a  core  nucleotide 
sequence and the gene for the peptide was constructed by overlapping PCR. The 
amplified  gene  was  cloned  into  pRSET–A  vector  and  transformed  into  salt 
inducible  expression  host  E.  coli  GJ1158.  The  expression  results  show  high 
yields of soluble recombinant fusion peptide (0.52 g/L) from salt-inducible E. 
coli. The recombinant peptide was purified by the IMAC purification system and 
cleaved by enterokinase. The digested product was further purified and 0.12 g/L 
of biologically active recombinant cationic antimicrobial peptide was obtained. In 
vitro  analysis  of  the  purified  peptide demonstrated  high  antimicrobial  activity 
against  both  Gram  positive  and  Gram  negative  bacteria  devoid  of  hemolytic 
activity. Therefore, this synthetic cationic antimicrobial peptide could serves as 
an promising agent over chemical antibiotics. In this study, a synthetic cationic 
antimicrobial peptide was designed, cloned and expressed from salt-inducible E. 
coli  GJ1158  using  cost  effective  media  in  the  large  scale  production  of 
antimicrobial peptide and its biological activity was analysed against different 
Gram positive and negative organisms.  
 
Key  words:  synthetic  antimicrobial  peptide,  in  silco  techniques,  pRSET-A, 
IMAC purification, entirokinase, antimicrobial activity 
 
Introduction 
The discovery, development and clinical exploitation of 
antibiotics are one of the most significant medical advances 
in twentieth century (Hancock, 1997). However, the usage of 
antibiotics towards potential pathogens have been over used 
or  used  improperly,  owing  to  resistance  or  multidrug 
resistance,  which  is  emerged  rapidly  in  many  microbial 
species  (Robert  &  Moellering,  2003).  The  pharmaceutical 
industry  has  continuously  met  this  need  by  modifying  the 
existing  antibiotics.  Despite  the  success  to  date  in 
antimicrobial  development,  the  inexorable,  ongoing ISSN: 1314-6246  Perevali et al.  J. BioSci. Biotech. 2013, 2(3): 181-188. 
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emergence  of  resistance  worldwide  continues  to  spur  the 
search  for  novel  anti-infectives  to  replace  or  supplement 
conventional antibiotics. So, there is an immediate demand to 
combat antibiotic-resistant microbes and scientists have begun 
to search for antimicrobial drugs in vertebrates, invertebrates 
and even bacteria and fungi living in the earth's most extreme 
environments (Bals, 2000). 
Antimicrobial  peptides  are  the  upcoming  therapeutic 
molecules  as  alternative  drugs  to  the  antibiotics.  These 
peptides  have  a  good  scope  in  current  antibiotic  research 
(Raventos et al., 2005). Antimicrobial peptides work against 
a wide range of pathogenic organisms in different ways and 
mechanisms where there will be almost negligible of getting 
resistance  by  the  organism  against  these  peptides.  Usually 
these  antimicrobial  peptides  bear  the  size  of  10 -50  amino 
acids  and  show  its  antimicrobial  activity  by  interacting, 
disturbing  their  cell  wall,  cell  membrane  and  at various 
intracellular  targets  ( Epand  &  Vogel,  1999 ).  These 
antimicrobial  peptides  are  identified  in  various  prokaryotic 
and eukaryotic sources, but all these molecules are facing the 
problems viz., fast proteolysis, a poor absorption due to their 
hydrophilicity, and  high  cost  of  development,  systemic  and 
local toxicity (Andersons et al., 1991). To avoid these hurdles, 
a  progressive  research  is  going  on  to  produce  the   peptide 
antibiotics at large scale using recombinant DNA technology. 
The most efficient method should be from Escherichia coli 
because  of  its  well  understood  genetic  nature  and  most 
inexpensive  mode  of  production  (Cipakova  et  al.,  2004; 
Hwang et al., 2001; Lee et al., 2000; Miller et al., 1998; Pyo 
et al., 2004; Rao et al., 2004; Zhang et al., 1998). 
The  present  work  has  been  carried  out  to  design, 
synthesize  an  array  of  antimicrobial  peptides  based  on 
following  parameters  i.e.,  conformation  (X),  charge  (Q), 
amphipathicity  (A),  hydrophobicity  (H),  polar  angle  (θ) 
(Yeaman & Yount, 2003). These peptides were analyzed by 
using  various  in  silco  techniques.  The  ideal  peptide  was 
amplified  by  PCR  methodology  and  expressed  in  a  non–
pathogenic industrially feasible E. coli expression system and 
was analyzed by in vitro plate methods for its antimicrobial 
activity against different microorganisms. 
Materials and Methods 
Strains, plasmids and enzymes 
E.  coli  DH5α  (MTCC  1652),  Pseudomonas
  putida 
(MTCC  102),  Micrococcus  luteus  (MTCC  106),  Bacillus 
subtilis (MTCC 511), Staphylococcus
 aureus (MTCC 87) and 
E. coli K12 (MTCC 1302) are procured from the Microbial 
Type  Culture  Collection  (MTCC),  Institute  of  Microbial 
Technology,  Chandigarh,  India.  E.  coli  GJ1158  is  kindly 
donated by Prof. J. Srinivasa Rao, Department of Chemical 
Engineering, Bapatla College of Engineering, Bapatla. E. coli 
DH5α  is  used  as  the  primary  host  for  construction  and 
propagation of plasmids. E. coli GJ1158 is used for peptide 
expression. Industrial feasible vector pRSET-A is procured 
from  Invitrogen.  All  molecular  biology  grade  enzymes, 
oligonucleotides  and  purification  kits  are  procured  from 
Sigma-Aldrich, Bangalore, India. 
Media preparation and culture conditions 
LBON (LB without NaCl) was used as seed culture. The 
expression studies were carried out in Glucose yeast extract 
medium  (GYEON):  Na2HPO4  –  6  g/L,  KH2PO4  –  3  g/L, 
NH4Cl – 1 g/L, Yeast extract – 5 g/L, Glucose – 5 g/L, 1M 
MgSO4 – 2 mL, TMM – 1 mL (Al2(S04)3.7H2O – 10 mg/L, 
CuSO4.H2O – 2 mg/L, H3BO4 – 1 mg/L, MnCl3.4H2O – 20 
mg/L,  NiCl2.6H2O  –  1  mg/L,  Na2MoO4.2H2O  –  50  mg/L, 
ZnSO4.7H2O – 50 mg/L, FeSO4 – 50 mg/L). The initial pH of 
the medium was not adjusted to any value before autoclaving 
at 121ﾰC for 15 to 20 min resulting in an initial pH value in 
the  range  of  pH  6.9  to  7.2.  The  autoclaved  medium  was 
inoculated aseptically with 4% of overnight fresh culture. The 
flask was kept on rotary shaker at 37ﾰC. NaCl was excluded 
while working with E. coli GJ1158. 
Computational tools  
Online computational tools viz., PROTPARAM, HNN and 
ANTIMICROBIAL  PEPTIDE  DATABASE  were  used  to 
check various physicochemical properties, secondary structure 
and antimicrobial property of designed peptides. Initially, we 
considered factors like conformation, charge, hydrophobicity 
and polar angle are chosen randomly to analyze five peptide 
sequences.  Often  the  peptide  sequences  were  submitted  to 
PROTPARAM  and  it  computes  various  physicochemical 
properties. Later, the secondary structure of the peptide was 
predicted  using  HNN,  which  plays  a  crucial  role  in 
antimicrobial  action  of  the  peptide.  At  last,  antimicrobial 
peptide  database  was  used  to  predict  the  antimicrobial 
property of the chosen peptide. 
Construction of synthetic gene by PCR 
The chosen peptide sequence was translated back to get 
the  nucleotide  sequence,  which  is  the  prerequisite  for 
constructing  the  synthetic  gene  to  the  peptide  by  PCR 
methodology. The nucleic acid sequence corresponding to the ISSN: 1314-6246  Perevali et al.  J. BioSci. Biotech. 2013, 2(3): 181-188. 
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synthetic  peptide  cassette  was  synthesized  according  to  the 
codon bias of E. coli. As per the design a 78 bp sized core 
nucleotide with two forward and reverse overlapping primers 
carrying the enzyme sites Bam HI and Hind III at 5’ regions 
were used to amplify the synthetic gene. PCR program was 
carried out at 95ﾰC for 5 min, 32 cycles at 95ﾰC for 1 min, 
64ﾰC for 1 min, 72ﾰC for 1 min and a final extension cycle at 
72ﾰC  for  10  min.  Later,  the  PCR  product  was  purified  by 
using Qiagen PCR purification kit.  
Cloning of synthetic gene into expression plasmid pRSET-A 
The plasmid vector pRSET-A, a 2.9 kb cytosolic bacterial 
expression vector with T7 promoter was used for cloning the 
gene of interest. The vector DNA (pRSET-A) and the insert 
DNA  (Synthetic  gene)  were  digested  with  BamHI  and 
HindIII restriction enzymes and ligated using T4 DNA ligase. 
The ligation mixture was transformed into the E. coli DH5α 
competent cells for propagation of the recombinant plasmid. 
A  positive  control  plasmid  (pGEX)  was  used  in  the 
experiments  to  verify  the  transformation  efficiency.  Cells 
with  no  DNA  added  to  serve  as  a  negative  control.  The 
recombinant  plasmid  (pRSET-A  –  cationic  antimicrobial 
peptide)  was  confirmed  by  using  PCR  with  gene  specific 
primers and restriction digestion. 
Heterologous expression using E. coli GJ1158 
The recombinant DNA was isolated and transformed into 
E.  coli  GJ1158  for  further  expression  studies.  The 
recombinant bacterial expression host was grown in LBON 
media  supplemented  with  ampicillin  (100  µg/ml)  at  37ﾰC. 
When the OD reaches to 0.6 to 0.8, 5% of grown culture was 
aseptically  transferred  to  GYEON  medium  with  antibiotic 
(100 µg/ml) and incubate on shaker to an OD600 of 1.0. The 
culture broth was induced with 200 mM NaCl and incubated 
at 37ﾰC for the production of recombinant peptide. After 4 h 
of  induction,  the  induced  culture  was  harvested  by 
centrifugation  at  13,800  rpm  for  10  min.  The  pellet  thus 
obtained  was dissolved  in PBS and equal concentration  of 
SSB. Later analyze the peptide expression using 18% tricine–
SDS–PAGE  and  peptide  concentration  was  determined  by 
Lowry method using BSA as a standard. 
Soluble form of the peptide 
In order to know the soluble form of the peptide, after 
induction,  10  ml  of  the  induced  cell  culture  was  pelleted 
down and STE buffer (100 mM NaCl, 10 mM Tris HCl, 1 
mM  EDTA)  was  added  to  the  pellet  and  mixed  well.  The 
samples were centrifuged at 4ﾰC at 13,800 rpm for 20 min 
and supernatant labelled as S-1. In continuation, NTE buffer 
was added to the pellet and subjected to sonication (10 cycles 
on  time,  10  cycles  off  time  and  5  min  total  time).  The 
sonicated samples were centrifuged at 13,800 rpm for 20 min 
at 4ﾰC and the supernatant labelled as S-2. NTET buffer (100 
mM NaCl, 10 mM Tris HCl, 1 mM EDTA, 1% Triton X-100 
and 2 M Urea) was added to the pellet and mixed well and 
centrifuged at 13,800 rpm for 20 min at 4ﾰC. The supernatant 
was  labelled  as  S-3  and  solubulizing  buffer  (50  mM 
NaH2PO4, 20 mM Tris, 100 mM NaCl and 8 M Urea) was 
added to the pellet and labelled as S-4. Peptide analysis was 
done using 18% separating gel to all the tubes labelled S1, 
S2, S3 and S4. 
Purification of recombinant cationic antimicrobial peptide 
The recombinant peptide carrying an N-terminal 6x His 
tag  was  expressed  in  E.  coli  GJ1158  and  purified  using 
affinity  chromatography  with  Ni
2+-  resin  under  hybrid 
conditions. In order to purify recombinant peptide, 400 mg 
wet cells were obtained from a freshly grown 50 ml culture in 
LBON  and  GYEON,  containing  the  appropriate  antibiotic. 
The cells were harvested and centrifuged at 13,800 rpm for 
20 min at 4ﾰC and the pellet attained was suspended in 6 ml 
of guanidinium lysis buffer containing 7 M guanidine HCl, 
22 mM sodium phosphate, 510 mM NaCl with pH 7.8 at 4ﾰC 
for 1 h. The cell lysate was again centrifuged at 13,800 rpm 
for 20 to 15 min at 4ﾰC. A volume of 5 ml cell lysate was 
purified on a column containing 2 ml resin equilibrated with  
denaturing  binding  buffer,  incubated  for  45  min  at  room 
temperature with gentle hand shaking for several times. The 
column was washed with 2 ml of denaturing wash buffer and 
twice with 2 ml of native wash buffer. The bounded peptide 
was eluted with 2 ml of native elution buffer and analysed on 
18% separating gel against to protein marker. 
Antimicrobial  assay  and  determination  of  minimal 
inhibitory concentration (MIC) 
Antimicrobial activity was tested by top agar assay and 
also by the radial diffusion  method on both Gram-positive 
(Staphylococcus
  aureus)  and  Gram-negative  (Pseudomonas
 
putida  and  E.  coli  K12)  bacteria  (Asoodeh  et  al.,  2004). 
Bacteria were first grown in LB (Luria-Bertani) broth to an 
OD600 of 0.8. A 10 μL of the bacterial culture was added to 8 
mL  of  LB  broth  with  0.7%  agar  and  poured  in  petri  dish 
containing  25  mL  of  1.5%  LB  agar.  After  the  top  agar 
harden, a 10 μL of the test sample was added on the surface 
of  the  top  agar  and  completely  dried  before  incubating 
overnight at 37ﾰC.  ISSN: 1314-6246  Perevali et al.  J. BioSci. Biotech. 2013, 2(3): 181-188. 
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If  sample  containing  antimicrobial  activity,  a  zone  of 
clearance  was  formed  on  the  surface  of  the  top  agar 
representing the inhibition of bacterial growth and ampicillin 
was used as a control. 
The peptide was further tested for its minimal inhibitory 
concentration (MIC) on  various bacterial strains (Xu et al., 
2006). Various concentrations ranging from 5 μg to 25 μg/ml 
of peptide (5 μg, 10 μg, 15 μg, 20 μg and 25 μg/ml) was 
added to the optimal diluted bacterial cultures of both Gram 
positive and Gram negative bacteria and incubated at 37ﾰC 
for  3  h.  Further,  the  three  bacterial  cultures  of  above 
mentioned  concentrations  were  transferred,  spread  on  agar 
plates  and  incubated  at  37ﾰC  for  overnight.  The  MIC  of 
peptide concentration was recorded. 
Hemolytic assay 
The  hemolytic  activity  of  the  cationic  antimicrobial 
peptide  was  determined  with  sheep  erythrocytes  based  on 
radial diffusion assay and the release of hemoglobin from the 
cells  or  the  lysis  of  erythrocytes  describes  the  hemolytic 
activity  of  the  peptide  (Concei￧ão  et  al.,  2006).  The  well 
punched on the solidified blood agar medium was filled with 
20 µl cationic antimicrobial peptide and 0.2% triton X-100, 
which  was  100%  hemolytically  active.  The  plates  were 
incubated at 37ﾰC for overnight to determine the hemolytic 
activity of the peptide on the erythrocytes.  
Results 
Designing and analysis of the cationic antimicrobial peptide 
The  factors  chosen  for  designing cationic  antimicrobial 
peptide  as  conformation,  charge,  hydrophobicity  and  polar 
angle  are  selected  randomly  for  analyzing  five  peptide 
sequences. Often one stable peptide sequence was obtained 
from  the  PROTPARAM  for  the  input  sequence  of  NH2-
CLKVRIWFK-COOH  (molecular  weight  1192.5)  based  on 
various computed parameters. Theoretical pI 10.06, N-terminal 
of the sequence considered is C (Cys), estimated half-life of 
1.2  hours  (mammalian  reticulocytes,  in  vitro),  >20  hours 
(yeast,  in  vivo);  >10  hours  (Escherichia  coli,  in  vivo)  and 
instability index (II) is computed to be 5.28. The predicted  
secondary  structure  of  a  peptide  from    HNN  shows  that 
sequence length was 9, α–helix (Hh) 0.00%, 310 helix (Gg) 
0.00%, Pi helix (Ii) 0.00%, β–bridge (Bb 0.00%, extended 
strand  (Ee)  77.78%,  β–turn  (Tt)  0.00%,  bend  region  (Ss) 
0.00%, random coil (Cc) 22.22%, ambigous state 0.00% and 
other states 0.00%. This shows that the peptide has extended 
strand structure in solution, which is homologous with tigerinin.  
After  binding  to  lipid  membrane,  the  structural 
conformation  differs  from  solution  structure.  Based  on  the 
antimicrobial properties like total hydrophobic ratio 6 %, total 
net  charge +3, peptide binding potential (Boman  index) 0.61 
kcal/mol of peptide through the antimicrobial peptide database. 
This peptide may interact with membranes and has a chance to 
be an antimicrobial peptide. 
Construction of the synthetic gene 
The sequence of the peptide chosen for investigation is 
NH2-CLKVRIWFK-COOH. For effective expression and to 
avoid  the  detrimental  effects  of  the  synthesized  cationic 
peptide in host  system, a 26 amino acid length expression 
cassette containing anionic spacer was designed as “M” (as a 
cleavage site for cyanogen bromide) - “CLKVRIWFK” (as 
cationic  peptide)  -  “M”  -  “EAED”  (as  an  anionic  spacer 
peptide) - “M” - “ CLKVRIWFK” - “M”. As per the design 
the nucleotide sequence was translated back from the peptide 
sequence  and  synthetic  gene  construction  (5’-
ATGTGCCTTAAAGTCCGTATTTGGTTTAAAATGGAG
GCGGAGGACATGTGCCTGAAGGTGCGCATCTGGTTC
AAGATG-3’)  was  carried  out  using  overlapping  PCR. 
Primers  were  designed  as  per  the  strategy,  which  includes 
forward primer: 5’-CGCGGATCCATGTGCCTTAAAGTC-
3’  (24  mer,  BamHI  cleavage  site  is  in  bold)  and  reverse 
primer:  5’-GGGAAGCTTTTACATCTTGAACCAGAT-3’ 
(27  mer,  HindIII  cleavage  site  is  in  bold)  for  large  scale 
amplification.  A  number  of  amplification  reactions  were 
performed to optimize the annealing temperature and at the 
temperature of 64ﾰC, an efficient amplification the synthetic 
gene was observed. The results of the PCR methodologies 
were analyzed and confirmed the 99 bp amplified synthetic 
gene product on 2% agarose gel by running against a 100 bp 
DNA ladder (Figure 1). 
Generation of recombinant DNA 
The resulting PCR product was digested with BamHI and 
HindIII  and  ligated  into  the  pRSET-A  plasmid  that  was 
digested with the same restriction enzymes to generate  the 
complex cationic antimicrobial peptide/pRSET-A (Figure 2). 
The  ligation  mixture  was  transformed  into  E.  coli  DH5α 
competent cells for propagation of the recombinant plasmids 
(Figure 3). The recombinant plasmid was confirmed by PCR 
with gene specific primers and the desired product size of 99 
bp DNA was identified against a 100 bp DNA ladder (Figure 
4). ISSN: 1314-6246  Perevali et al.  J. BioSci. Biotech. 2013, 2(3): 181-188. 
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Figure  1.  PCR  optimization  for  synthetic  antimicrobial 
peptide. M: 100 base pair DNA ladder; 1: Ve; 2: Annealing 
temperature at 58
oC; 3: Annealing temperature at 61
oC; 4: 
Annealing temperature at 64
oC; 5: Annealing temperature at 
66
oC; 6: Annealing temperature at 69
oC. 
 
 
 
Figure  2.  Schematic  representation  of  the  construction  of 
cationic  antimicrobial  peptide–pRSET-A  gene.  Bold  letters 
represents  synthetic  cationic  antimicrobial  peptide.  Italic 
letters indicates termination codon. 
 
 
 
Figure 3. Transformation of SG-pRSET-A into E.coli GJ1158 
bacterial cells. 1: –Ve plate; 2: pRSET-A ( +Ve plate); 3: SG 
– pRSET-A (Ligation sample). 
 
Figure 4. PCR for the plasmids from transformed plate with 
gene specific primers. M: 100bp DNA ladder; 1 to 7: PCR 
for the plasmid DNA from colonies 
 
Expression  and  purification  of  synthetic  cationic 
antimicrobial peptide 
For  the  expression  studies,  the  E.  coli  expression  host 
GJ1158  was  used  for  NaCl  induction.  The  confirmed 
recombinant plasmid DNA was transformed into competent 
E. coli expression host GJ1158 using heat shock method. To 
enhance the expression levels of heterologous peptide, LBON 
medium was used as seed medium and GYEON medium was 
used  for  the  expression  of  recombinant  peptide.  Cells 
containing  the  recombinant  DNA  were  grown  up  to  0.8–1 
OD600 and induced with appropriate inducer NaCl (200 mM), 
for 4 h at 37ﾰC. The induced peptide expression profiles were 
resolved on 18% tricine–SDS–PAGE. The synthetic peptide 
was visualized on the gel at the position corresponding to the 
reference or standard protein (Figure 5).  
 
Figure  5.  Tricine  SDS-PAGE  analysis  of  recombinant 
protein expression  (antimicrobial peptide) at different time 
intervals. 1: GJ 1158 non-induced; 2: GJ 1158 induced; 3: 
low  molecular  weight  protein  marker;  4:  Sg  pRSET-A  GJ 
1158 non-induced; 5: Sg pRSET-A GJ 1158 induced–induced 
1; 6: Sg pRSETA GJ 1158 induced–induced 2; 7: Sg pRSET-
A GJ 1158 induced–induced 3 
 
Out of four samples, S-2 fraction shows that the synthetic 
peptide  was  highly  soluble  (i.e.  96%  of  the  total  fusion ISSN: 1314-6246  Perevali et al.  J. BioSci. Biotech. 2013, 2(3): 181-188. 
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peptide)  and  accounted  for  0.52  g/L  of  the  total  soluble 
protein. Later, the recombinant peptide  was purified by the 
IMAC purification system and cleaved by enterokinase. The 
digested product was further purified and achieved about 0.12 
g/L of biologically active recombinant cationic antimicrobial 
peptide.  To  check  the  recombinant  purified  peptide   18% 
tricine–SDS–PAGE was used. Results showed that 2.9 kDa 
band corresponding to low molecular weight protein marker 
(Figure 6). 
 
Figure  6.  Tricine  SDS-PAGE  analysis  of  IMAC  purified 
antimicrobial peptide. Lane 1: purified peptide; Lane 2: low 
molecular weight protein marker. 
 
Antimicrobial and hemolytic activity 
The  antimicrobial  activity  assay  was  performed  to 
determine the activity of the purified recombinant synthetic 
cationic antimicrobial peptide. Figure 7 shows that zone of 
clearance  around  the  well  containing  recombinant 
antimicrobial  peptide.  The  control  well  shows  no  zone  of 
inhibition.  
 
Figure  7.  Inhibitory  zone  evaluations  of  recombinant 
synthetic antimicrobial peptide on growth of Staphylococcus 
aureus. 1: Ampicillin (10 μg/ml); 2: 1 mM PPB (pH 7) as 
negative  control;  3:  Recombinant  synthetic  peptide  (10 
μg/ml). 
The  minimal  inhibitory  concentration  (MIC)  of  the 
purified  recombinant  antimicrobial  peptide  against  Gram-
positive and Gram-negative bacteria are shown in Table 1. 
The  MIC  values  were  in  the  range  of  15–25  µg/ml.  The 
antimicrobial effect of different concentration of the cationic 
antimicrobial peptide on E. coli K12 growth was illustrated in 
Figure  8.  Some  antimicrobial  peptides  exhibit  hemolytic 
activities  but  no  hemolytic  activity  was  observed  after 
overnight incubation using the concentration of 5 – 50 μg/ml, 
indicating  that  the  cationic  antimicrobial  peptide  was  not 
toxic to red blood cells. 
 
Table  1.  Minimal  inhibitory  concentrations  (MICs)  of 
synthetic  cationic  peptide  on  Gram  positive  and  Gram 
negative microorganisms. 
Microorganisms  MIC
a (µg/ml) 
Gram positive 
Micrococcus luteus 
Bacillus subtilis 
Staphylococcus aureus 
 
15 
20 
15 
Gram negative 
Pseudomonas
 putida 
E. coli DH5α 
 
15 
25 
a  Experiments were carried out in duplicates. 
 
Figure 8. The effect of cationic antimicrobial peptide on the 
growth of E. coli K12 monitored by measuring the OD600 nm. 
Experiments were performed in duplicates.  
Discussion 
Nowa days, antimicrobial peptides are extensively studied 
owing to their possible medical applications. Researchers are 
always in hunt for effective production of biologically active ISSN: 1314-6246  Perevali et al.  J. BioSci. Biotech. 2013, 2(3): 181-188. 
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antimicrobial  peptides  in  large  quantities  with  affordable 
prices (Robert & Moellering, 2003; Hancock, 2001). Out of 
different  antimicrobial  peptides  available  in  the  market, 
cationic synthetic antimicrobial peptides are promising agents 
(Projan, 2003). Owing to the requirement for large quantity 
of antimicrobial peptides, we required a production method 
using economically feasible E. coli GJ1158 with low cost of 
medium  instead  of  using  LBON.  To  express  the  synthetic 
antimicrobial  peptides  in  prokaryotic  host  E.  coli,  anionic 
spacer peptide and cleavage site for cyanogen bromide are 
used to neutralize the innate toxic activity to host bacterial 
cells and to increase their expression levels (Xu et al., 2006; 
Cao  et  al.,  2005;  Lai  et  al.,  2005;  Sanz  et  al.,  2005; 
Shlyapnikov et al., 2008). 
In  the  present  study  a  9  amino  acid  synthetic 
antimicrobial  peptide  was  designed  by  using  the 
bioinformatics  tools  viz.,  ProtParam,  Hierarchical  Neural 
Network,  Antimicrobial  peptide  database.  The  designed 
peptide was translated back into a core nucleotide sequence 
and the gene for the peptide was constructed by overlapping 
PCR  methodology.  Synthesized  gene  was  cloned  into 
pRSET-A  vector  and  transformed  into  E.coli  host  system 
GJ1158. The transformation of E.coli GJ1158 by pRSET-A– 
cationic  antimicrobial  peptide  was  successful,  as 
demonstrated  by  PCR  analysis.  Three  colonies  which 
generated  well-amplified  products  were  used  for  a  small-
scale expression trial, and the amount of recombinant peptide 
was  determined  by  tricine–SDS  polyacrylamide  gel 
electrophoresis (tricine–SDS–PAGE). The expression levels 
of antimicrobial peptide in this study was 20 – 30% where in 
other studies it is ranged from 11 to 44% of total protein (Cao 
et  al.,  2005;  Huang  et  al.,  2008;  Li  et  al.,  2007).  The 
bactericidal  assay  of  cationic  antimicrobial  peptide  peptide 
showed  high  activity  to  Gram-positive  and  Gram-negative 
bacteria. The peptide was devoid of toxic nature to red blood 
cells and had high activity against bacteria indicates that it 
has  potent  antibacterial  agent.  Further  clinical  trials  could 
prove  this  synthetic cationic antimicrobial peptide  to  be  an 
effective antimicrobial agent and it can be effectively used on a 
commercial  scale  for  control  of  several  severe  human 
pathogenic microorganisms. 
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